A biologic drug found lowering LDL cholesterol when other lipid lowering drug such as statins are not showing adequate result. The drug is in experimental phase and named as REGN727.
The drug is biologic lipid lowering drug class. Researchers reported 75 percent reduction in LDL (bad cholesterol) level when REGN727 administered with statin drug such as Mevacor and generic Lipitor.
The study included 180 patients with LDL level of 100mg/dL. All the participants were given generic lipitor along with REGN727 injection. Result of the study represented at yearly meeting of American College of Cardiology.
40% reduction in LDL level was reported when 50mg of the drug was administered once every 2 weeks. LDL level lowered by 64 percent when dose of the drug raised by 50% i.e. 100mg. 150mg of REGN727 found to be more effective as it reduced LDL by 72 percent.
Reduction was only 5 percent for combination of statin drug and placebo.
Dosage of the drug adjusted to once a month but it does not produce effect as good as once in two week dose, said Dr James McKenney – lead author of the study. Dr McKenney is CEO of National Clinical Research in Richmond.
Working mechanism of new drug is quite different than that of statin drugs (cholesterol lowering drugs). The new drug lowered LDL by preventing action of a protein known as PCSK9.
No comments:
Post a Comment